Mariia Oliinyk

Mariia Oliinyk

Auto-generated profile, based on publicly available information

Mariia Oliinyk

Department of Rheumatology, Sint Maartenskliniek , Nijmegen

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in CARTILAGE
Verified
Journal Article
Open access
MOMariia Oliinyk
Mariia Oliinyk
SMSimon C. Mastbergen
Simon C. Mastbergen
AMAnne Karien C. A. Marijnissen
Anne Karien C. A. Marijnissen
DFDavid T. Felson
David T. Felson
DHDavid J. Hunter
David J. Hunter
Mylène JansenMylène Jansen
Mylène Jansen
Objective: To analyze and synthesize the information available from five pivotal, large-scale, multicenter, observational studies (CHECK, OAI, FNIH Biomarkers Consortium, IMI-APPROACH, and MOST) focusing on knee osteoarthritis (OA), which can be used to elucidate disease progression, risk factors, and the effectiveness of potential interventions. Design: For this narrative review, a comprehensive literature search and data extraction from official web pages and scientific databases were conducted to compare methodologies, in- and exclusion criteria, outcomes, and cohort characteristics across the studies. Thematic, comparative, and qualitative analyses were employed to identify trends, commonalities, and disparities among the findings. Results: The studies collectively enhanced understanding of the onset and progression of knee OA, and in several of the studies, hip OA, emphasizing the importance of both systemic and local risk factors. Advanced imaging and biomarkers are important components in all the cohorts, with the goal of aiding early diagnosis and tracking disease progression. All cohorts evaluated unique markers generally not available in the other cohorts, while other factors overlap, suggesting possibilities for combining or cross-validating between cohorts. Conclusions: The collaborative efforts of major OA research significantly advance our understanding of knee OA. These studies highlight the importance of a multifaceted approach, integrating advanced imaging, biomarkers, and longitudinal data to tackle the complexities of OA. By synthesizing findings and addressing knowledge gaps such as heterogeneity of patients and used measurements, and use of novel pain measures, future research can develop more effective diagnostic tools and treatments, ultimately enhancing the quality of life for OA patients.

2 January 2026 in Rheumatology Advances in Practice
Verified
Journal Article
Open access
MOMariia Oliinyk
Mariia Oliinyk
JVJohanna E Vriezekolk
Johanna E Vriezekolk
HSHenk Schers
Henk Schers
SHSjoerd Heslinga
Sjoerd Heslinga
KBKaren Bevers
Karen Bevers
CPCalin Popa
Calin Popa
Objectives: To explore the implementation of cardiovascular risk management (CVRM) in Dutch RA patients from the perspective of rheumatologists and patients. Methods: An online survey was conducted among Dutch rheumatologists, rheumatology physician assistants (PAs) and RA patients. Healthcare providers completed a 37-item adapted version of the Determinants of Implementation Behavior Questionnaire to assess various aspects of CVRM implementation behaviour on a 7-point Likert scale. Simultaneously, a 13-item questionnaire was administered to RA patients to gather experiences related to CVRM. Data for both surveys were collected online between 23 September and 1 December 2024. Results: A total of 85 healthcare providers [93% rheumatologists, mean age 47.2 years (s.d. 8.8), 72% female] and 145 RA patients [mean age 58 years (s.d. 12.6), 89% female] completed the survey. Providers did not seem to lack (self-reported) knowledge on CVRM, yet significant implementation challenges were identified across several domains, including skills, professional roles and beliefs about capabilities. Time constraints, limited resources, insufficient financial support and the absence of local protocols were cited as major barriers. From the patient perspective, only 39% reported being informed about RA-related cardiovascular risks, mostly by rheumatologists. Rheumatologists frequently provided guidance on physical activity (21%), while general practitioners were more active in managing traditional cardiovascular risk factors, prescribing medications (23%) and offering self-management advice (16%). Conclusion: Our study highlights the main challenges in implementing CVRM in daily practice, indicating the need for the development of targeted strategies to overcome these barriers.

1 June 2017
Verified
Journal Article
Closed access
DVDmytro Vasylyev
Dmytro Vasylyev
LCL Chernobay
L Chernobay
OVO Vasylieva
O Vasylieva
М(Мария (Mariia) Олейник (Oliinyk)
Мария (Mariia) Олейник (Oliinyk)
MVM Vashuk
M Vashuk

30 December 2024 in Ukrainian Therapeutical Journal
Verified
Journal Article
Open access
PDF file
LZL. V. Zhuravlyova
L. V. Zhuravlyova
MOM. O. Oliinyk
M. O. Oliinyk
YSY. K. Sikalo
Y. K. Sikalo
VFV. O. Fedorov
V. O. Fedorov
ЮСЮ. К. Сікало
Ю. К. Сікало
Rheumatoid arthritis (RA) is an autoimmune disease that can be accompanied by complex liver involvement. The diagnosis and differentiation of these conditions are often complicated by the rarity of liver biopsies and the similarity of symptoms to other liver diseases. Viral hepatitis B and C in the context of rheumatoid arthritis can mimic rheumatological manifestations, further complicating timely diagnosis and worsening the prognosis for patients with rheumatoid arthritis. This literature review aims to systematize knowledge and assess the risks associated with the treatment of rheumatoid arthritis in patients with viral hepatitis B and C. Additionally, the article aims to provide recommendations for screening and treatment of viral hepatitis in these patients. The review is based on the analysis of available literature for the last ten years, including clinical trials, meta‑analyses, systematic reviews, and recommendations for the treatment of viral hepatitis in patients with rheumatoid arthritis. According to the literature, liver involvement in patients with rheumatoid arthritis can be caused by the disease itself, its treatment, or viral infections. Research results emphasize the importance of regular monitoring of liver function and screening for viral hepatitis B and C before starting rheumatoid arthritis treatment and during the use of immunosuppressive drugs. The integration of screening for viral hepatitis B and C into standard medical protocols for patients with rheumatoid arthritis before starting immunosuppressive therapy is essential. The timely detection of these infections is crucial because the treatment of hepatitis and immunosuppressive therapy for rheumatoid arthritis are interconnected and require a comprehensive approach. Adaptation of treatment depending on the status of viral infection is necessary to minimize liver risks and optimize the outcomes of rheumatoid arthritis treatment.

31 March 2025 in Ukrainian Therapeutical Journal
Verified
Journal Article
Open access
PDF file
LZL. V. Zhuravlyova
L. V. Zhuravlyova
YSY. K. Sikalo
Y. K. Sikalo
VFV. O. Fedorov
V. O. Fedorov
TKT. I. Khovrat
T. I. Khovrat
MOM. O. Oliinyk
M. O. Oliinyk
ТХТ. І. Ховрат
Т. І. Ховрат
Localized scleroderma (Morphea) is a chronic autoimmune connective tissue disease characterized by fibrosis of the skin and underlying tissues, which may lead to disability and cosmetic problems. The disease usually lacks systemic manifestations such as internal organ involvement, Raynaud’s phenomenon, or telangiectasia. In rare cases, morphea progresses rapidly, is resistant to standard therapy, and requires alternative treatment methods. The aim of the article is to enhance physicians’ awareness regarding the latest advancements in understanding the diverse clinical variants of morphea, with a focus on therapeutic strategies and their effectiveness within the context of an individualized treatment approach. The article presents modern approaches to understanding the pathogenesis and clinical variability of morphea, emphasizing diagnostic difficulties and features of the choice of therapeutic strategy in rheumatological practice. Particular attention is paid to treatment options that go beyond traditional therapy, particularly the use of immunobiological agents. The role of a multidisciplinary approach in the management of such patients, which includes the cooperation of rheumatologists, dermatologists, and other specialists, is also highlighted. We present a case of a 51‑year‑old patient with rapidly progressive morphea, resistant to methotrexate. The initial symptoms included erythematous spots, skin induration, and swelling of the lower extremities, which later spread to the upper extremities, despite 1.5 years of therapy with methotrexate (15 mg/week) and methylprednisolone (8 mg/day). Physical examination revealed widespread induration and hyperpigmentation in 4 of the 7 body zones without signs of systemic organ damage. A biopsy confirmed the diagnosis of localized scleroderma (morphea), clinically defined as a generalized form, active phase, stage II (modified Rodnan skin score=18, Localized Scleroderma Skin Damage Index=47, Modified Localized Scleroderma Skin Activity Index=44, general assessment of the patient’s condition by the doctor (PGA)=70). Methotrexate was replaced with mycophenolate mofetil (500 mg twice a day with further intensification) in combination with low doses of methylprednisolone (4 mg/day), which after 2 months halted disease progression. This case highlights the variability of the clinical course of morphea and underscores the importance of careful clinical observation, timely diagnosis, and individualized approach to the treatment of such patients, as well as the need for further research to optimize therapeutic strategies for this pathology. The presented modern data will help to raise awareness of physicians about the variety of clinical manifestations of morphea and the possibilities of using alternative treatments.

14 September 2021 in PROBLEMS OF ENDOCRINE PATHOLOGY
Verified
Journal Article
Open access
PDF file
LZLarysa Zhuravlyova
Larysa Zhuravlyova
MOMariia Oliinyk
Mariia Oliinyk
YSYulia Sikalo
Yulia Sikalo
The number of patients with diabetes mellitus in the world has been progressively increasing in recent years, therefore, the fight against complications of diabetes mellitus is an important problem of our time. The purpose of our review is to analyze the literature data on the risks of osteoporosis in patients with diabetes mellitus, effective diagnostic methods, as well as current recommendations for the treatment and prevention of osteoporosis in this category of patients. Results. We have processed and analyzed literary sources and internationalrecommendations, which identify the main mechanisms and risk factors that contribute to the development of osteoporosis in patients with type 1 and 2 diabetes mellitus; methods for the timely diagnosis of osteoporosis are indicated, methods for correcting the condition of patients with diabetes mellitus, which can help prevent the development of osteoporosis in this group of patients, are given. The current recommendations for the treatment of osteoporosis in men and women are presented. Conclusions. Taking into account the data of the analysis of literary sources, osteoporosis can be considered one of the complications of diabetes mellitus. Today, densitometry and fracture risk assessment FRAX are quite sensitive methods for early diagnosis of osteoporosis in patients with type 1 diabetes mellitus, but not sufficient for patients with type 2 diabetes mellitus, therefore there is a need to determine the trabecular bone index during densitometry, as well as additional actions when assessing the risk of fractures on the FRAX scale. Therapy of patients with osteoporosis with concomitant diabetes mellitus should be based on the achievement of target glycemic levels and the use of bisphosphonates with target level of calcium and vitamin D.